Trial may bring hope to children with rare muscle disorder

Australian researchers are at the forefront of a new clinical trial that may bring hope to children with Duchenne muscular dystrophy (DMD) and their families.

Organisation/s: Murdoch Children’s Research Institute (MCRI)

Funder: The study was funded by Antisense Therapeutics.

Media release

From: Murdoch Children’s Research Institute (MCRI)

Australian researchers are at the forefront of a new clinical trial that may bring hope to children with Duchenne muscular dystrophy (DMD) and their families.

The phase II trial, funded by Antisense Therapeutics, will test a potential new drug for DMD in children who have become wheelchair-bound by the disease. For these patients, there are few existing treatments and the disease usually leads to progressive loss of muscle function over time.

Murdoch Children’s Research Institute (MCRI) is leading the Australian arm of the international study, which also includes The Children’s Hospital at Westmead in Sydney and the Queensland Children’s Hospital, as well as hospitals in the UK, Bulgaria and Turkey.

MCRI’s Dr Ian Woodcock, a paediatric neurologist, recently enrolled the first Australian patients into the clinical trial to test the new therapy called ATL1102. The drug, developed by scientists in Melbourne, targets the chronic inflammation which is thought to be responsible for much of the deterioration experienced by patients with DMD. The trial will assess the safety, tolerability and potential efficacy of the drug in boys aged 10-18 years.

Dr Woodcock said, “there is a substantial unmet need for new treatments in Duchenne muscular dystrophy. My colleagues and I have seen encouraging early-stage data with this therapy and are hopeful that it may have a future role to play in the treatment of this challenging disease.”

It is expected that the study will enrol about 12 patients in Australia, with recruitment due to complete in the first quarter of 2024.

About 1000 people have DMD in Australia. The genetic disease, which almost exclusively affects boys, results in progressive muscle weakness, leaving most patients wheelchair-bound by their teenage years. Life expectancy for these patients is in the mid-twenties.

Results of the ongoing trial are expected to be available in the second half of 2024. If positive, the trial may lead to discussions with the Therapeutic Goods Administration regarding potential marketing approval.

Available for interview:

Dr Ian Woodcock, MCRI neuromuscular disorders researcher

SOURCE

Leave a Comment